---
title: "Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289464811.md"
description: "In recent data, it was found that a single dose of vispa-cel led to strong and lasting responses in second-line (2L) patients with large B-cell lymphoma (LBCL). The results showed an impressive 82% overall response rate (ORR) and a 67% complete response (CR) rate. Additionally, the median progression-free survival (mPFS) reached 17.1 months. The treatment was generally well-tolerated, suggesting it can be safely administered on an outpatient basis, potentially allowing for broader use in community centers."
datetime: "2026-06-11T12:04:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289464811.md)
  - [en](https://longbridge.com/en/news/289464811.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289464811.md)
generator: "portal-rs"
---

# Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

In recent data, it was found that a single dose of vispa-cel led to strong and lasting responses in second-line (2L) patients with large B-cell lymphoma (LBCL). The results showed an impressive 82% overall response rate (ORR) and a 67% complete response (CR) rate. Additionally, the median progression-free survival (mPFS) reached 17.1 months. The treatment was generally well-tolerated, suggesting it can be safely administered on an outpatient basis, potentially allowing for broader use in community centers.

### Related Stocks

- [CRBU.US](https://longbridge.com/en/quote/CRBU.US.md)

## Related News & Research

- [Caribou Biosciences Q2 net loss narrows](https://longbridge.com/en/news/295849330.md)
- [The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership](https://longbridge.com/en/news/298111249.md)
- [Bristol-Myers Squibb (BMY) Following Camzyos Data And Zola Cel Pause Still Looks Fully Valued](https://longbridge.com/en/news/298117403.md)
- [Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns](https://longbridge.com/en/news/298117865.md)
- [Will Long‑Term Camzyos Data and Real‑World Evidence Change Bristol Myers Squibb's (BMY) Narrative?](https://longbridge.com/en/news/298073103.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**